GlassScriptPhysician profile
Jaime A Martinez
NPI 1962713909
$8,688.00
in general payments reported to CMS, 2019-2025
35 companies · $30.68 in 2025
The $30.68 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,297 · 2020: $1,957 · 2021: $2,017 · 2022: $1,543 · 2023: $779 · 2024: $63.14 · 2025: $30.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.04 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,171.89 | 2019-2023 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,093.90 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $1,036.97 | 2019-2024 | Ozempic, Wegovy |
| Lilly USA, LLC | $966.30 | 2019-2023 | Mounjaro, Trulicity |
| Janssen Pharmaceuticals, INC | $626.23 | 2019-2022 | |
| Pfizer INC. | $381.74 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $360.87 | 2019-2022 | |
| Amgen INC. | $359.59 | 2019-2021 | |
| Abbvie INC. | $338.30 | 2021-2023 | |
| Glaxosmithkline, LLC. | $295.50 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $272.08 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $252.07 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.89 | 2019-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $175.52 | 2022 | |
| Amarin Pharma, INC. | $128.56 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $101.46 | 2021-2022 | |
| Daiichi Sankyo INC. | $85.83 | 2021-2022 | |
| Esperion Therapeutics, INC. | $70.51 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.30 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $69.03 | 2022-2023 | Ingrezza |
| Astellas Pharma US INC | $63.57 | 2020-2021 | |
| Exact Sciences Corporation | $61.55 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $61.50 | 2020 | |
| Sanofi-Aventis U.S. LLC | $58.62 | 2020-2023 | |
| Avanir Pharmaceuticals, INC. | $53.97 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.82 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $47.68 | 2019 | |
| Exeltis, USA INC. | $45.65 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $35.97 | 2021 | |
| Corcept Therapeutics | $35.14 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $30.63 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.06 | 2023 | Gvoke Hypopen |
| Medtronic Minimed, INC. | $21.02 | 2019 | |
| Mylan Specialty L.P. | $15.77 | 2019 | |
| Sanofi Pasteur INC. | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.